DOCSLIB.ORG

Download of These Slides, Please Direct Your Browser to the Following Web Address

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Download of These Slides, Please Direct Your Browser to the Following Web Address Clinical Roundtable Monograph Clinical Advances in Hematology & Oncology October 2015 Advances in the Management of Chemotherapy-Induced Nausea and Vomiting: New Data From Recent and Ongoing Trials Discussants Eric Roeland, MD Director of Clinical Research in Symptom Intervention Assistant Clinical Professor of Medicine University of California, San Diego Moores Cancer Center La Jolla, California Matti S. Aapro, MD Dean of the Multidisciplinary Oncology Institute A CME Activity Clinique de Genolier Approved for Genolier, Switzerland 1.25 AMA PRA Category 1 Credit(s) TM Lee S. Schwartzberg, MD Professor of Medicine Chief, Division of Hematology & Oncology Release Date: October 2015 The University of Tennessee Health Science Center Expiration Date: October 31, 2016 Memphis, Tennessee Estimated time to complete activity: 1.25 hours Project ID: 11026 Abstract: Chemotherapy-induced nausea and vomiting (CINV) is among the most feared and debilitating adverse events experienced by cancer patients. Left unaddressed, CINV symptoms not only decrease quality of life, but may also affect patients’ willingness to continue chemotherapy treatment. Detailed guidelines are available that outline best practices for prophylaxis of acute and delayed CINV. However, adherence to guideline recommendations continues to be suboptimal, and many patients still suffer unnecessarily from CINV. In addition, breakthrough/refractory CINV continues to present particular challenges. The development of effective CINV treatments with diverse mechanisms of action has expanded the options available for preventing symptoms. The US Food and Drug Administration has recently approved several new therapies for the management of CINV. NEPA is a fixed-dose combination of netupitant (300 mg) plus palonosetron (0.5 mg). In combination with dexamethasone, NEPA has demonstrated superior efficacy to palonosetron alone in patients receiving highly or moderately emetogenic chemotherapy. Rolapitant is a next- generation neurokinin 1 (NK1) receptor antagonist. Both palonosetron and rolapitant have proven particularly effective in controlling delayed CINV. Regimens that combine a serotonin 5-hydroxytryptamine–3 receptor antagonist, an NK1 receptor antagonist, and a corticosteroid now represent the standard of care for managing both acute and delayed CINV in patients receiving highly emetogenic chemotherapy. This activity is supported by an independent Jointly provided by Postgraduate Institute for educational grant from Eisai Inc. Medicine and Millennium Medical Publishing Target Audience Eric Roeland, MD—Speakers bureau: Teva and Eisai; Data Safety Monitor- This activity has been designed to meet the educational needs of oncologists, ing Board: Cellceutix; Advisory board: Eisai, Inform Genomics, and Helsinn. hematologists, and oncology nurses involved in the management of cancer pa- Consulting: Eisai tients receiving chemotherapy. Lee S. Schwartzberg, MD—Consultant: Eisai, Helsinn, Merck, and Tesaro Matti S. Aapro, MD—Study grants: Helsinn, Eisai, Merck, Roche, and Statement of Need/Program Overview Chemotherapy-induced nausea and vomiting (CINV) is among the most feared Janssen; Consultant or speaker: Helsinn, Eisai, Merck, Roche, and Janssen and debilitating adverse events experienced by cancer patients. Symptoms not only decrease quality of life, but may also lead patients to delay or postpone chemo- The planners and managers reported the following financial relationships or rela- therapy. Patients must be educated regarding CINV management before they begin tionships to products or devices they or their spouse/life partner have with com- chemotherapy and then asked about specific symptoms after treatment. Options for mercial interests related to the content of this CME activity: prevention and treatment of CINV are based on the emetogenic risk of the chemo- therapy and the type of CINV (acute, delayed, anticipatory, or breakthrough/refrac- The following PIM planners and managers, Trace Hutchison, PharmD; Samantha tory). The US Food and Drug Administration has recently approved new therapies Mattiucci, PharmD, CHCP, Judi Smelker-Mitchek, RN, BSN, and Jan Schultz, for the management of CINV. NEPA is a fixed-dose combination of netupitant RN, MSN, CHCP hereby state that they or their spouse/life partner do not have plus palonosetron. In combination with dexamethasone, NEPA has demonstrated any financial relationships or relationships to products or devices with any com- superior efficacy over palonosetron alone in patients receiving highly or moderately mercial interest related to the content of this activity of any amount during the past emetogenic chemotherapy. Rolapitant is a next-generation neurokinin 1 receptor 12 months. Jacquelyn Matos: No real or apparent conflicts of interest to report. antagonist. Both palonosetron and rolapitant have proven particularly effective in Maggie Merchant, PhD: No real or apparent conflicts of interest to report. controlling delayed CINV. Detailed management guidelines, with recommenda- tions based on data from phase 3 clinical trials, provide effective approaches for pre- Method of Participation vention and treatment. Adherence to guidelines is suboptimal but can be improved There are no fees for participating in and receiving CME credit for this activity. with the use of programs incorporating provider education sessions, monthly audit- During the period October 2015 through October 31, 2016, participants must feedback sessions, and risk assessment tools. 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the post-test by recording the best answer to each question Educational Objectives in the answer key on the evaluation form; 4) complete the evaluation form; and After completing this activity, the participant should be better able to: 5) mail or fax the evaluation form with answer key to Postgraduate Institute for Medicine. You may also complete the post-test online at www.cmeuniversity. • Describe the impact, incidence, and risk factors of CINV com. On the navigation menu, click on “Find Post-test/Evaluation by Course” • Distinguish chemotherapy regimens with high, moderate, and low emeto- and search by course ID 11026. Upon registering and successfully completing genic risk the post-test with a score of 75% or better and submitting the activity evaluation, • Implement strategies for CINV prevention and management based on rec- your certificate will be made available immediately. Processing credit requests ommendations from guidelines online will reduce the amount of paper used by nearly 100,000 sheets per year. • Evaluate the efficacy and safety data supporting the use of approved anti- emetic agents in the prevention of CINV A statement of credit will be issued only upon receipt of a completed activity • Assess results from recent and ongoing clinical trials in CINV management evaluation form and a completed post-test with a score of 75% or better. Your statement will be emailed to you within three weeks. Accreditation Statement This activity has been planned and implemented in accordance with the ac- Media creditation requirements and policies of the Accreditation Council for Monograph Continuing Medical Education (ACCME) through the joint provider- ship of Postgraduate Institute for Medicine and Millennium Medical Pub- Disclosure of Unlabeled Use lishing, Inc. The Postgraduate Institute for Medicine is accredited by the This educational activity may contain discussion of published and/or inves- ACCME to provide continuing medical education for physicians. tigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled Credit Designation indications. PIM, Millennium Medical Publishing, Inc., and Eisai Inc. do not The Postgraduate Institute for Medicine designates this enduring material for a recommend the use of any agent outside of the labeled indications. maximum of 1.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the Disclosure of Conflicts of Interest official prescribing information for each product for discussion of approved Postgraduate Institute for Medicine (PIM) requires instructors, planners, man- indications, contraindications, and warnings. agers, and other individuals who are in a position to control the content of this activity to disclose any real or apparent conflict of interest (COI) they may Disclaimer have as related to the content of this activity. All identified COI are thoroughly Participants have an implied responsibility to use the newly acquired informa- vetted and resolved according to PIM policy. PIM is committed to provid- tion to enhance patient outcomes and their own professional development. The ing its learners with high-quality CME activities and related materials that information presented in this activity is not meant to serve as a guideline for pa- promote improvements or quality in healthcare and not a specific proprietary tient management. Any procedures, medications, or other courses of diagnosis or business interest of a commercial interest. treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications
Load more

Recommended publications
  • MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
    1 ANTIEMETIC GUIDELINES: MASCC/ESMO MASCC/ESMO ANTIEMETIC GUIDELINE 2016 With Updates in 2019 Organizing and Overall Meeting Chairs: Matti Aapro, MD Richard J. Gralla, MD Jørn Herrstedt, MD, DMSci Alex Molassiotis, RN, PhD Fausto Roila, MD © Multinational Association of Supportive Care in CancerTM All rights reserved worldwide. 2 ANTIEMETIC GUIDELINES: MASCC/ESMO These slides are provided to all by the Multinational Association of Supportive Care in Cancer and can be used freely, provided no changes are made and the MASCC and ESMO logos, as well as date of the information are retained. For questions please contact: Matti Aapro at [email protected] Chair, MASCC Antiemetic Study Group or Alex Molassiotis at [email protected] Past Chair, MASCC Antiemetic Study Group 3 ANTIEMETIC GUIDELINES: MASCC/ESMO Consensus A few comments on this guideline set: • This set of guideline slides represents the latest edition of the guideline process. • This set of slides has been endorsed by the MASCC Antiemetic Guideline Committee and ESMO Guideline Committee. • The guidelines are based on the votes of the panel at the Copenhagen Consensus Conference on Antiemetic Therapy, June 2015. • Latest version: March 2016, with updates in 2019. 4 ANTIEMETIC GUIDELINES: MASCC/ESMO Changes: The Steering Committee has clarified some points: 2016: • A footnote clarified that aprepitant 165 mg is approved by regulatory authorities in some parts of the world ( although no randomised clinical trial has investigated this dose ). Thus use of aprepitant 80 mg in the delayed phase is only for those cases where aprepitant 125 mg is used on day 1. • A probable modification in pediatric guidelines based on the recent Cochrane meta-analysis is indicated.
    [Show full text]
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • Antiemetics/Antivertigo Agents
    Antiemetic Agents Therapeutic Class Review (TCR) May 1, 2019 No part of this publication may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, digital scanning, or via any information storage or retrieval system without the express written consent of Magellan Rx Management. All requests for permission should be mailed to: Magellan Rx Management Attention: Legal Department 6950 Columbia Gateway Drive Columbia, Maryland 21046 The materials contained herein represent the opinions of the collective authors and editors and should not be construed to be the official representation of any professional organization or group, any state Pharmacy and Therapeutics committee, any state Medicaid Agency, or any other clinical committee. This material is not intended to be relied upon as medical advice for specific medical cases and nothing contained herein should be relied upon by any patient, medical professional or layperson seeking information about a specific course of treatment for a specific medical condition. All readers of this material are responsible for independently obtaining medical advice and guidance from their own physician and/or other medical professional in regard to the best course of treatment for their specific medical condition. This publication, inclusive of all forms contained herein, is intended to be educational in nature and is intended to be used for informational purposes only. Send comments and suggestions to [email protected]. May 2019 Proprietary Information. Restricted Access – Do not disseminate or copy without approval. © 2004-2019 Magellan Rx Management. All Rights Reserved. 3 FDA-APPROVED INDICATIONS Drug Manufacturer Indication(s) NK1 receptor antagonists aprepitant capsules generic, Merck In combination with other antiemetic agents for: (Emend®)1 .
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • HHS Template for Reports, with Instructions
    Texas Vendor Drug Program 1.1 Drug Use Criteria: Substance P/Neurokinin1 Receptor Antagonists Publication History 1. Developed December 2003. 2. Revised September 2020; September 2018; September 2016; May 2015; August 2013; June 2013; September 2011; October 2009; February 2006; January 2006. Notes: Information on indications for use or diagnosis is assumed to be unavailable. All criteria may be applied retrospectively; prospective application is indicated with an asterisk [*]. The information contained is for the convenience of the public. The Texas Health and Human Services Commission is not responsible for any errors in transmission or any errors or omissions in the document. Medications listed in the tables and non-FDA approved indications included in these retrospective criteria are not indicative of Vendor Drug Program formulary coverage. Prepared by: • Drug Information Service, UT Health San Antonio. • The College of Pharmacy, The University of Texas at Austin. 1 1 Dosage [*] Current therapies for chemotherapy-induced nausea/vomiting (CINV) and post- operative nausea and vomiting (PONV) target corticosteroid, dopamine, and serotonin (5-HT3) receptors. In the central nervous system, tachykinins and neurokinins play a role in some autonomic reflexes and behaviors. Aprepitant is a selective human substance P/neurokinin 1 (NK1) antagonist with a high affinity for NK1 receptors and little, if any, attraction for corticosteroid, dopamine, or 5-HT3 receptors. Rolapitant (Varubi®), the newest substance P/NK1 antagonist, is FDA- approved to prevent delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults. Combination therapy including netupitant, a substance P/NK1 antagonist and palonosetron, a selective 5-HT3 receptor antagonist (Akynzeo®), is now available to prevent acute and delayed CINV with initial and repeat chemotherapy courses including, but not limited to, highly emetogenic chemotherapy in adults.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Quality Issues in Caring for Older People
    Doctoral Thesis - Tesis Doctoral Quality issues in caring for older people: • Appropriateness of transition from long-term care facilities to acute hospital care • Potentially inappropriate medication: development of a European list Anna Renom Guiteras Prof. Gabriele Meyer Prof. Ramón Miralles Basseda Martin Luther University Halle-Wittenberg Universitat Autònoma de Barcelona Halle (Saale) & Barcelona, Catalonia University of Witten/Herdecke Spain Witten Germany Programa de doctorat en Medicina Departament de Medicina, Facultat de Medicina Universitat Autònoma de Barcelona Barcelona, 2015 13 Contents 15 1. Introduction • Research context • Background of the research topics • Pesetaio of the ailes 23 2. Summary and discussion of the results 31 3. Conclusions 37 4. References 47 5. Articles • Article 1: Renom-Guiteras A, Uhrenfeldt L, Meyer G, Mann E. Assessment tools for determining appropriateness of admission to acute care of persons transferred from long-term care facilities: a systematic review. BMC Geriatr. 2014;14:80 • Article 2: Renom-Guiteras A, Meyer G, Thürmann PA. The EU(7)-PIM list: a list of potentially inappropriate medications for older people consented by experts from seven European countries. Eur J Clin Pharmacol. 2015;71(7):861-75 77 6. Annexes • Annex 1.1 (article 1) - Additional file 1: Studies dealing with assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 1.2 (article 1) - Additional file 2: Characteristics of the assessment tools for determining appropriateness of hospital admissions among residents of LTC facilities. • Annex 2.1 (article 2) - Appendix 1: Complete EU(7)-PIM list • Annex 2.2 (article 2) - Appendix 2: Questionable Potentially Inappropriate Medications (Questionable PIM): results of the Delphi survey.
    [Show full text]
  • Metoclopramide: an Antiemetic in Chemotherapy Induced Nausea and Vomiting
    Central Journal of Drug Design and Research Bringing Excellence in Open Access Mini Review *Corresponding author Jørn Herrstedt, Department of Oncology, Odense University Hospital, DK-5000, Odense C, Denmark, Tel: Metoclopramide: An Antiemetic 45-6541-3634; Email: Submitted: 13 January 2017 Accepted: 16 March 2017 in Chemotherapy Induced Published: 17 March 2017 ISSN: 2379-089X Nausea and Vomiting Copyright © 2017 Herrstedt et al. 1 2 Signe Ladegaard Harder and Jørn Herrstedt * OPEN ACCESS 1Department of Oncology, Odense University Hospital, Denmark 2Department of Oncology, Odense University Hospital and the University of Southern Keywords Denmark, Denmark • Metoclopramide • Chemotherapy Abstract • Nausea • Vomiting Chemotherapy induced nausea and vomiting (CINV) are two of the most • Emesis feared adverse events experienced by cancer patients undergoing chemotherapy. Metoclopramide was derived from procainamide in the 1950s and one of the first drugs investigated in the prophylaxis of nausea and vomiting induced by chemotherapy. The breakthrough came in 1981 with the recognition that high-dose metoclopramide was effective and tolerable in the prevention of cisplatin-induced nausea and vomiting. A combination of high- dose metoclopramide and a corticosteroid was the standard antiemetic recommendation until the serotonin (5-HT)3-receptor antagonists, ondansetron, granisetron, tropisetron and dolasetron became available in the beginning of the 1990s. The development of these highly selective (5-HT)3-receptor antagonists with a superior effect and a preferable tolerability profile has limited the use of metoclopramide to be prescribed as a rescue antiemetic, when guideline recommended antiemetic therapy fails. ABBREVIATIONS The emetic risk of chemotherapy is divided in high emetic risk (risk of vomiting 0-24 hours after chemotherapy > 90%), CINV: Chemotherapy-Induced Nausea and Vomiting; moderate emetic risk (30-90%), low emetic risk (10-30%) and MCP: Metoclopramide; NK -Receptor Antagonist: Neurokinin 1 minimal emetic risk (< 10%).
    [Show full text]
  • The Handbook of Cannabis Therapeutics: from Bench to Bedside
    Handbook of Cannabis Therapeutics From Bench to Bedside 9780789030979 Handbook of Cannabis Therapeutics From Bench to Bedside Size: 212 x 152mm Spine size: 26 mm Color pages: Binding: Paperback THE HAWORTH PRESS® Haworth Series in Integrative Healing Ethan Russo Editor The Last Sorcerer: Echoes of the Rainforest by Ethan Russo Professionalism and Ethics in Complementary and Alternative Medicine by John Crellin and Fernando Ania Cannabis and Cannabinoids: Pharmacology, Toxicology, and Therapeutic Potential by Franjo Grotenhermen and Ethan Russo Modern Psychology and Ancient Wisdom: Psychological Healing Practices from the World’s Religious Traditions edited by Sharon G. Mijares Complementary and Alternative Medicine: Clinic Design by Robert A. Roush Herbal Voices: American Herbalism Through the Words of American Herbalists by Anne K. Dougherty The Healing Power of Chinese Herbs and Medicinal Recipes by Joseph P. Hou and Youyu Jin Alternative Therapies in the Treatment of Brain Injury and Neurobehavioral Disorders: A Practical Guide edited by Gregory J. Murrey Handbook of Cannabis Therapeutics: From Bench to Bedside edited by Ethan B. Russo and Franjo Grotenhermen Handbook of Cannabis Therapeutics From Bench to Bedside Ethan B. Russo, MD Franjo Grotenhermen, MD Editors Routledge Taylor &. Francis Croup NEW YORK AND LONDON First Published by The Haworth Press, Inc., 10 Alice Street, Binghamton, NY 13904-1580. Transferred to Digital Printing 2010 by Routledge 270 Madison Ave, New York NY 10016 2 Park Square, Milton Park, Abingdon, Oxon, OX14 4RN For more information on this book or to order, visit http://www.haworthpress.com/store/product.asp?sku=5741 or call 1-800-HAWORTH (800-429-6784) in the United States and Canada or (607) 722-5857 outside the United States and Canada or contact [email protected] © 2006 by The Haworth Press, Inc.
    [Show full text]
  • The Significance of NK1 Receptor Ligands and Their Application In
    pharmaceutics Review The Significance of NK1 Receptor Ligands and Their Application in Targeted Radionuclide Tumour Therapy Agnieszka Majkowska-Pilip * , Paweł Krzysztof Halik and Ewa Gniazdowska Centre of Radiochemistry and Nuclear Chemistry, Institute of Nuclear Chemistry and Technology, Dorodna 16, 03-195 Warsaw, Poland * Correspondence: [email protected]; Tel.: +48-22-504-10-11 Received: 7 June 2019; Accepted: 16 August 2019; Published: 1 September 2019 Abstract: To date, our understanding of the Substance P (SP) and neurokinin 1 receptor (NK1R) system shows intricate relations between human physiology and disease occurrence or progression. Within the oncological field, overexpression of NK1R and this SP/NK1R system have been implicated in cancer cell progression and poor overall prognosis. This review focuses on providing an update on the current state of knowledge around the wide spectrum of NK1R ligands and applications of radioligands as radiopharmaceuticals. In this review, data concerning both the chemical and biological aspects of peptide and nonpeptide ligands as agonists or antagonists in classical and nuclear medicine, are presented and discussed. However, the research presented here is primarily focused on NK1R nonpeptide antagonistic ligands and the potential application of SP/NK1R system in targeted radionuclide tumour therapy. Keywords: neurokinin 1 receptor; Substance P; SP analogues; NK1R antagonists; targeted therapy; radioligands; tumour therapy; PET imaging 1. Introduction Neurokinin 1 receptor (NK1R), also known as tachykinin receptor 1 (TACR1), belongs to the tachykinin receptor subfamily of G protein-coupled receptors (GPCRs), also called seven-transmembrane domain receptors (Figure1)[ 1–3]. The human NK1 receptor structure [4] is available in Protein Data Bank (6E59).
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]